1.58
price up icon0.64%   0.01
after-market After Hours: 1.53 -0.05 -3.16%
loading
Pliant Therapeutics Inc stock is traded at $1.58, with a volume of 686.08K. It is up +0.64% in the last 24 hours and up +26.40% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.57
Open:
$1.625
24h Volume:
686.08K
Relative Volume:
0.61
Market Cap:
$96.99M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.5113
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+17.91%
1M Performance:
+26.40%
6M Performance:
-85.82%
1Y Performance:
-87.72%
1-Day Range:
Value
$1.57
$1.64
1-Week Range:
Value
$1.33
$1.64
52-Week Range:
Value
$1.1001
$16.10

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Name
Pliant Therapeutics Inc
Name
Phone
650-481-6770
Name
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Employee
171
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PLRX's Discussions on Twitter

Compare PLRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PLRX
Pliant Therapeutics Inc
1.58 96.38M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-04-25 Resumed Cantor Fitzgerald Neutral
Mar-04-25 Downgrade Needham Buy → Hold
Mar-03-25 Downgrade Leerink Partners Outperform → Market Perform
Mar-03-25 Downgrade Stifel Buy → Hold
Feb-10-25 Downgrade Canaccord Genuity Buy → Hold
Feb-10-25 Downgrade Citigroup Buy → Neutral
Feb-10-25 Downgrade H.C. Wainwright Buy → Neutral
Feb-10-25 Downgrade JP Morgan Overweight → Neutral
Feb-10-25 Downgrade Oppenheimer Outperform → Perform
Feb-10-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-10-25 Downgrade Wells Fargo Overweight → Equal Weight
Sep-09-24 Resumed Leerink Partners Outperform
Dec-08-23 Initiated Wells Fargo Overweight
May-18-23 Initiated Canaccord Genuity Buy
Apr-13-23 Initiated Robert W. Baird Outperform
Dec-14-22 Initiated Stifel Buy
Dec-07-22 Initiated JP Morgan Overweight
Sep-01-22 Initiated Citigroup Buy
Jul-20-22 Initiated SVB Leerink Outperform
May-25-22 Initiated Cantor Fitzgerald Overweight
Dec-10-21 Initiated Oppenheimer Outperform
Nov-24-21 Initiated RBC Capital Mkts Outperform
Nov-03-21 Initiated H.C. Wainwright Buy
Apr-20-21 Initiated BTIG Research Buy
Apr-05-21 Initiated Citigroup Buy
Jun-29-20 Initiated Citigroup Buy
Jun-29-20 Initiated Cowen Outperform
Jun-29-20 Initiated Needham Buy
Jun-29-20 Initiated Piper Sandler Overweight
View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

pulisher
10:36 AM

What drives Pliant Therapeutics Inc. stock priceAccelerated wealth expansion - Autocar Professional

10:36 AM
pulisher
Jul 22, 2025

Is Pliant Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What analysts say about Pliant Therapeutics Inc. stockConsistently profitable trades - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

Pliant Therapeutics Inc. Stock Analysis and ForecastHigh-profit trading signals - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Is Pliant Therapeutics Inc. stock a growth or value playHigh Return Potential - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Pliant Therapeutics Inc. stock price move sharplyDefensive Stock Picks with Upside - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st

Jul 15, 2025
pulisher
Jul 15, 2025

How Pliant Therapeutics Inc. stock performs during market volatilityTrade Ready Signal - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Pliant Therapeutics Inc. stock attracts strong analyst attentionLow Risk ROI Maximization - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Pliant Therapeutics Inc (PLRX) Stock: Navigating a Year of Volatility - investchronicle.com

Jul 10, 2025
pulisher
Jul 03, 2025

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail

Jul 03, 2025
pulisher
Jul 01, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN) - The Globe and Mail

Jul 01, 2025
pulisher
Jun 30, 2025

Pliant Therapeutics, Inc.(NasdaqGS: PLRX) dropped from Russell 2500 Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - The Manila Times

Jun 28, 2025
pulisher
Jun 27, 2025

Pliant Therapeutics Provides Update on BEACON-IPF | PLRX Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Pliant Therapeutics Provides Update on BEACON-IPF - GlobeNewswire

Jun 27, 2025
pulisher
Jun 27, 2025

Pliant Therapeutics Provides Update on BEACON-IPF | PLRX Stock N - GuruFocus

Jun 27, 2025
pulisher
Jun 14, 2025

Pliant Therapeutics Inc’s (PLRX) Stock Is Harder To Predict Than You Think - Stocksregister

Jun 14, 2025
pulisher
Jun 10, 2025

Pliant Therapeutics amends corporate bylaws, holds stockholder vote By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 09, 2025

Pliant Therapeutics amends corporate bylaws, holds stockholder vote - Investing.com

Jun 09, 2025
pulisher
May 21, 2025

Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics presents new fibrosis treatment data - Investing.com

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire

May 21, 2025
pulisher
May 14, 2025

How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister

May 14, 2025
pulisher
May 12, 2025

Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks

May 12, 2025
pulisher
May 09, 2025

Another Bay Area biotech company announces layoffs - MSN

May 09, 2025
pulisher
May 09, 2025

Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 09, 2025
pulisher
May 08, 2025

Pliant (PLRX) Prepares to Release Topline Results from BEACON-IP - GuruFocus

May 08, 2025

Pliant Therapeutics Inc Stock (PLRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Cap:     |  Volume (24h):